Look at what Gilead spent on Pharmasett (11 billion for a drug in Phase 3) and what they will net after a decade of treatments.
The buy of Pharmasett was visionary.
The management of the resulting CF's looks pretty poor.
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes